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Abstract: Metabolic syndrome (MetS) is characterised by metabolic abnormalities that increase the risk
of developing type 2 diabetes mellitus and cardiovascular disease. Altered levels of circulating ghrelin,
several adipokines and inflammatory markers secreted from adipose tissue, such as leptin, adiponectin,
tumor necrosis factor alpha, are observed in overweight and obese individuals. We assessed the effect
of supplementation with low doses of a cod protein hydrolysate (CPH) on fasting and postprandial
levels of acylated ghrelin, as well as fasting levels of adiponectin, leptin and inflammatory markers
in subjects with MetS. A multicentre, double-blinded, randomized controlled trial with a parallel
group design was conducted. Subjects received a daily supplement of CPH (4 g protein, n = 15) or
placebo (0 g protein, n = 15). We observed no effect on fasting or postprandial levels of acylated
ghrelin, fasting levels of adiponectin (p = 0.089) or leptin (p = 0.967) after supplementation with CPH,
compared to placebo. Overall, our study showed that 8 weeks supplementation with a low dose of
CPH in subjects with MetS had no effect on satiety hormones or most of the inflammatory markers,
but the levels of high-sensitivity C-reactive protein were statistically significantly different in the
CPH-group compared to placebo group. The robustness and clinical relevance of these findings
should be explored in future studies with a larger sample size.
Keywords: cod protein hydrolysate; satiety hormones; inflammatory markers; metabolic syndrome
1. Introduction
Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities including abdominal
obesity, hypertriglyceridemia, low levels of high-density cholesterol, hyperglycemia and hypertension,
increasing the risk of cardiovascular disease and type 2 diabetes mellitus (T2DM) [1,2]. The pathogenesis
of MetS is not fully understood, but a genetic predisposition combined with a sedentary lifestyle and
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excessive caloric intake, are known to be important risk factors [3]. A positive energy balance over time
leads to increased storage of fat in the adipocytes with expansion of adipose tissue, resulting in increased
production of pro-inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-α) [3,4]. These cytokines and other signaling molecules secreted from the adipose tissue are
involved in several physiological processes in the body, such as regulation of energy homeostasis,
body fat accumulation and inflammation [5–7].
Inflammation is the immune system’s response to an injurious stimulus, initiating a cascade of
events promoting healing of the affected tissue [8]. Signaling pathways are activated as part of the
inflammatory response, leading to the release of inflammatory mediators, including interleukin-1
beta (IL-1β), IL-6 and TNF-α [9,10]. Even though the acute inflammatory response is essential,
the process may develop to a chronic inflammatory state, known to be involved in the development of
several chronic diseases, such as diabetes [9]. Fish consumption has been linked to reduced levels of
inflammatory mediators, such as IL-6 and TNF-α in rats [11,12] and healthy adults [13]. Lower levels
of C-reactive protein (CRP), a marker of inflammation, have been observed in insulin-resistant
subjects given a diet with lean fish (cod) for 4 weeks [14], with no effect observed when overweight
individuals were given a low dose of cod protein supplementation [15]. The mechanism behind the
possible anti-inflammatory effect of fish is largely unknown, but it has been suggested that the high
taurine content in fish may have anti-inflammatory properties by suppressing IL-6 and TNF-α [12,16].
There are also indications from cell and animal studies, that bioactive peptides from lean fish have
anti-inflammatory effects [9,17], with a need for further investigation in humans.
The secretion of IL-6, IL-8 and other cytokines are inhibited by adiponectin, a signaling molecule
released from adipose tissue [4,18]. This molecule is known to enhance insulin sensitivity [4],
and reduced levels have been reported in subjects with obesity and T2DM [5,19]. In contrast, increased
levels of leptin, a hormone involved in regulation of food intake and appetite [7,20], have been
reported in obese subjects [19]. Furthermore, consumption of fish and supplementation with n-3
polyunsaturated fatty acids (PUFAs) increase levels of adiponectin [19,21,22], with similar results
reported after supplementation with cod protein in overweight and obese subjects [23]. For leptin,
published data are conflicting [19,21,23,24]. As leptin and adiponectin seem to be altered in subjects
with obesity and associated with factors of MetS, an effect on these adipokines by supplementation
with fish protein, might be a possible preventive strategy for the development of MetS.
Ghrelin, a small peptide hormone secreted from the stomach, is an appetite-stimulating hormone
with the opposite effects of leptin [25]. The levels of ghrelin increase before a meal and decrease
postprandially [26], and is involved in regulation of appetite, energy balance and body weight [27].
Compounds that may inhibit the action of ghrelin and suppress appetite, may be beneficial for both
prevention and treatment of components of MetS, such as obesity, impairments in lipid metabolism
or glucose homeostasis [28]. We have previously reported the effect of low doses of a cod protein
hydrolysate (CPH) on fasting and postprandial levels of acylated ghrelin in healthy adults [29].
We observed that a single dose of 20 mg/kg body weight of CPH did not affect postprandial levels of
acylated ghrelin or sensations related to feeling of hunger, when compared to the control group [29].
Limited data exists on long-term supplementation of cod protein in a population with metabolic
abnormalities, yet it is an important abnormality to study. We have previously reported on the effects
on fasting and postprandial glucose metabolism, as well as lipid metabolism and body composition
in subjects with MetS after supplementation with 4 g of CPH for 8 weeks [30]. In the present study,
we aimed to investigate if daily supplementation with the same low dose of CPH for 8 weeks would
influence circulating levels of ghrelin, adiponectin, leptin, high-sensitivity CRP (hs-CRP) and a selection
of other inflammatory markers.
Nutrients 2020, 12, 3421 3 of 13
2. Materials and Methods
2.1. Study Design
We performed a multicenter, double-blinded, randomized parallel group trial with one daily dose
of 4 g CPH or placebo for 8 weeks. Here, we report secondary outcomes; fasting and postprandial levels
of acylated ghrelin and fasting levels of adiponectin, leptin and inflammatory markers. The study was
conducted according to the Declaration of Helsinki and all procedures were approved by the Regional
Committee for Medical and Health Research Ethics of Central Norway (2018/2163). Written informed
consent was obtained from all subjects. The trial is registered at www.clinicaltrials.gov (NCT03807752).
2.2. Subjects and Study Setting
We recruited participants between March and September 2019 in the Bergen and Ålesund area
(Norway) through an online recruitment questionnaire with advertisements on social media, at the
participating hospitals and at general practitioners’ offices. Inclusion criteria were diagnosis of MetS,
body mass index (BMI) between 27–35 kg/m2 and age between 40–70 years. Exclusion criteria were
intolerance or allergy to fish and/or shellfish, chronic diseases or medication that were likely to interfere
with the evaluation of study endpoints (e.g., T2DM, medications known to affect glucose metabolism),
acute infections, abuse of alcohol or drugs (assessed by a physician) or unwillingness to comply with
the study requirements. We included participants using calcium channel blockers (n = 3) agents acting
on the renin-angiotensin system (i.e., ACE inhibitor n = 2, AII-receptor agonist n = 5, AII-receptor
agonist/thiazide diuretic n = 3), since blood pressure was not an outcome. The participants were
excluded if they had recently started with the current medication, if they had changed the dose level
during the last 3 months or if it was changed during the study. Subjects using beta-blocking agents or
peripheral vasodilators were excluded.
In this study, the Joint Interim Statement definition of MetS was used [1], where three abnormal
findings out of five given risk factors qualifies for a diagnosis of MetS. The following risk factors and
criteria were used: serum triglycerides ≥ 1.7 mmol/L, high-density lipoprotein cholesterol < 1.0 mmol/L
in men and < 1.3 mmol/L in women, serum glucose ≥ 5.5 mmol/L, systolic blood pressure ≥ 130 mmHg
and/or diastolic blood pressure≥ 85 mmHg [1]. For waist circumference (WC), we used the International
Diabetes Federation cut-off points for central obesity: WC ≥ 94 cm in men, ≥ 80 cm in women [31].
2.3. Study Visits
After prescreening by telephone, we invited potential participants to a screening visit to
assess eligibility, including inclusion and exclusion criteria. The screening visit included a clinical
examination by a physician, review of medical history, measure of vital signs (blood pressure,
heart rate), anthropometric measures (height, weight and WC) and blood sampling. We measured
height (to the nearest 0.1 cm) and weight (to the nearest 0.1 kg) with an electronic scale (Seca 285,
SECA GmbH, Hamburg, Germany). For measurements of WC, the WHO recommendation was
followed [32,33]; the midpoint between the lower/inferior palpable rib and the top of iliac crest was
located, the participants had arms relaxed at the side and the measurements were made at the end
of normal expiration, using a measuring tape with constant tension. Changes in physical activity
during the study period, as well as changes to food consumption were prohibited. The participants
recorded their intake of food and drink in a three-day prospective food diary, before the baseline
visit and end of study visit. Energy and protein intake from the supplement were added to the end
of study dietary records (CPH group: 44 kcal, 4 g protein; placebo group: 46.5 kcal, 0 g protein).
Details about the end of study energy intake is reported in a previous publication [30]. Calculations of
energy and macronutrient intake were determined using “Kostholdsplanleggeren” (Norwegian Food
Safety Authority, Norwegian Directorate of Health, Oslo) [34]. The participants had to stop the use
of n-3 PUFA-containing dietary supplements for four weeks prior to starting the study, and this was
prohibited for the duration of the study.
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After inclusion, the participants attended two identical study visits: the baseline visit and end
of study visit (after 8 weeks of intervention). The participants came to the research facility between
08:00 AM–09:00 AM in a fasting state (no eating, drinking or use of any nicotine-containing substance
after 09:00 PM the previous evening). When they arrived, fasting blood samples were taken followed
by anthropometric measurements. Body composition was measured by a bioelectrical impedance
analysis device (Body Composition Analyzer, Tanita Corporation, Tokyo, Japan, BC-418 MA (model
used in Ålesund), or MC-180 MA (model used in Bergen)) according to the manufacturer’s instructions.
The participants then consumed a standardized breakfast meal (test meal) consisting of two slices
of semi-dark bread (50% whole wheat, 80 g weight), 10 g margarine, 25 g strawberry jam and 20 g
white cheese and 1.5 dL orange juice. The meal contained 1840 kJ (440 kcal), 69 g carbohydrate,
13.3 g protein, 14.3 g fat. The energy and macronutrient content of the test meal were calculated
using “Kostholdsplanleggeren” [34]. The meal had to be consumed within 15 min and was followed
by postprandial blood sampling. Blood was drawn from an antecubital vein prior to the test meal
(−20 min), at 0 min (i.e., immediately after the meal was consumed), and thereafter at 20, 40, 60, 80,
100 and 120 min. No coffee or tea were served during test hours, but we allowed free drinking of water.
We handed 8 weeks supply of the pre-packed test material (active or placebo) to the participants at
the end of the baseline study visit. They started the intervention on the following day and took the
supplement daily, 10 min before breakfast, for 8 weeks. Since the participants met fasting at both study
visit, they did not take the study supplement at home before the end of study visit.
2.4. Test Material
The test material was manufactured by Firmenich Bjørge Biomarin AS (Ålesund, Norway),
and delivered pre-packed in sealed plastic-coated aluminium bags. It was a lemon-flavored powder to
be mixed with 100 mL cold water before ingestion. The powder bags with intervention material (CPH)
contained 4 g of hydrolysed cod protein, 5 g glucose hydrate, 2 g maltodextrin, 0.025 g tastegram
powder flavour, 0.1 g lemongrass durarome taste and 0.7 g citric acid. The placebo contained 6.5 g of
maltodextrin, 0.2 g citric acid, and was otherwise identical to the intervention material. It was not
possible to identify the CPH-material from the placebo, according to flavour or appearance.
The CPH was made by enzymatic hydrolysis of fresh frozen meat (cutting and trimmings) of
Atlantic cod (Gadus morhua), adding the enzyme preparation Protamex® (Novozymes AS, Copenhagen,
Denmark) for 45 min, at 55 ◦C and pH 7.0. This was followed by inactivation of the enzyme, with heating
to 90 ◦C for 15 min. The peptide containing water-soluble fraction (the hydrolysate) was separated
from the indigested residue, followed by ultrafiltration and dehydration of the soluble phase to a 50%
dry matter concentrate. This was spray-dried to a powder. The spray-dried CPH powder contained
89% crude protein and <0.2% fat, 0% carbohydrate, <3.0% water, 10% ash, 0.1% NaCl, 1.7% sodium
and 0.07% chloride, by weight. Free amino acids accounted for 4.8% of the total amino acids in the
hydrolysate, and the ratio between essential amino acids: non-essential amino acids was 0.70. Analysis
of the molecular weight distribution, as well as the composition of amino acids and taurine content of
the spray dried CPH powder is given in a previous publication [35].
2.5. Analyses of Blood Samples
Albumin, prealbumin, leucocytes, thrombocytes, hemoglobin, sodium, potassium, alanine
aminotransferase, alkaline phosphatase, creatinine and aspartate aminotransferase, were analyzed at
inclusion and end of study by standard accredited methods at Department of Medical Biochemistry
and Pharmacology, Haukeland University Hospital (HUH), and Department of Medical Biochemistry,
Ålesund Hospital.
Serum for analyses of hs-CRP, adiponectin, leptin and inflammatory markers were obtained by
centrifugation of full blood at 2000× g at room temperature (20 ◦C) for 10 min after 30–60 min of
coagulation, using serum separator cloth activator tubes. Hs-CRP was analyzed by standard accredited
methods at the Department of Medical Biochemistry and Pharmacology, HUH. Serum adiponectin and
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leptin were analyzed using Human Adiponectin High Sensitivity ELISA kit (Cat. No.: RD191023100,
Biovendor, Brno, Czech Republic) and Human Leptin ELISA, Clinical Range kit (Cat. No: RD191001100,
Biovendor) respectively. TNF-α and IL 1β, IL 6, and IL 8 were analyzed by the Cytokine human
ultrasensitive magnetic 10-plex panel for LuminexTM platform (Cat.No: LHC6004M, Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA). Leptin, adiponectin, as well as the inflammatory
markers, were only measured and analyzed in the fasted stated.
Samples for ghrelin measurement were collected in Vacuette® EDTA Aprotinin tubes (Item No:
454261, Greiner Bio-One International GmbH, Kremsmünster, Austria), added 34 µL 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF) Ready-made solution (Item No: SBR00015,
Sigma-Aldrich, Saint-Louis, MO, USA), right after blood sampling. Plasma for fasting and postprandial
ghrelin at baseline and end of study was obtained by centrifugation of EDTA blood at 1800× g at
−4 ◦C for 10 min, within 20 min after blood sampling. Ghrelin levels were analyzed using the Ghrelin
Acylated Human Easy Sampling ELISA (Cat.No: RA194062500R, Biovendor)
2.6. Randomization
To allocate the study participants, we used wCRF®, a randomization and data collection system
developed by the Norwegian University of Science and Technology, Trondheim, Norway. The random
assignment order was created using block randomization, and we stratified for center (Ålesund or
Bergen). A person with no direct involvement in the study coded the test materials and the participants,
as well as all study personnel involved in the study implementation and data handling, were blinded
to group allocation.
2.7. Statistical Analyses
We performed statistical analyses using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp.,
Armonk, NY, USA) and GraphPad Prism version 8.4.2 (GraphPad Software, Inc., San Diego, CA, USA).
The Shapiro-Wilk test and histograms were used to evaluate normality. For data not following a normal
distribution and not improved by log-transformation, we used non-parametric tests. The Wilcoxon’s
Signed Rank Test was used to investigate changes from baseline to end of study within groups, and
the Independent Samples Mann Whitney U Test was used to compare changes (8 weeks—baseline)
between the CPH and placebo group at end of study. These data (adiponectin, leptin, hs-CRP and
inflammatory markers) are presented as median and interquartile range. A linear mixed-effects model
with repeated measures was used to examine group differences over time for fasting and postprandial
measurements of ghrelin. A Pearson’s correlation coefficient analysis was used to examine relationship
between fasting levels of acylated ghrelin at baseline and change in body weight (kg) and BMI (kg/m2).
The level of significance was set to p < 0.05. A power calculation was not done in the original study due
to lack of data to base it upon [30]. Therefore, no estimation of sample size of the current measurements
was done prior to the study. According to protocol, we planned to recruit 60 subjects in the study,
which is a number similar to what have been reported in other supplementation studies with low
doses of cod protein [15,36].
3. Results
3.1. Participant Characteristics
We screened a total of 147 participants for compliance with inclusion and exclusion criteria by
telephone and invited 68 participants for a screening visit. Fifty-eight attended the screening visit and
30 participants were included and completed the intervention according to study protocol (Figure 1).
Baseline characteristic are presented in Table 1.
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3.2. Adiponectin and Leptin
No statistically significant differences between the groups were observed for adiponectin (p = 0.806)
or leptin (p = 0.367) at baseline. At end of study, the fasting adiponectin concentration was significantly
increased within the CPH group (baseline: 7.98 (5.68, 11.06) µg/mL, end study: 8.84 (6.06, 13.7) µg/mL),
p = 0.008), with no changes observed within the placebo group (baseline: 7.89 µg/mL (7.06, 10.53),
end of study: 7.82 (7.07, 11.90) µg/mL, p = 0.910) (Figure 2a). The median adiponectin change
(8 weeks—baseline) in the CPH group was 0.56 (0.25, 1.71) µg/mL, and −0.12 (−0.56, 1.07) µg/mL in the
placebo group. When comparing the change in fasting levels of adiponectin, no statistically significant
difference between groups was observed (p = 0.089).
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Figure 2. Fasting serum levels of adiponectin (a) and leptin (b) in participants with metabolic syndrome
at baseline and after 8 weeks supplementation (end study) with cod protein hydrolysate (CPH) (n = 15)
or placebo (n = 15). The red horizontal line shows the median levels. p-values within groups were
calculated using the Wilcoxon’s Signed Rank Test. Statistically significant p-values are marked with an
asterisk (*).
No statistically significant differences in leptin levels within the CPH (baseline: 36.2 (18.2,
44.6) ng/mL, end study: 30.8 (16.8, 40.0) ng/mL, p = 0.733) or placebo group (baseline: 45.7 (17.1, 52.5)
ng/mL end study: 39.6 (20.8, 59.6) ng/mL, p = 0.910) were observed from baseline to end of study
(Figure 2b). The median leptin change in the CPH group was 0.30 (−3.27, 4.94) ng/mL, and 0.012 (−4.24,
8.98) ng/mL in the placebo group. When comparing the change in fasting levels of leptin, we did not
observe any statistically significant difference between groups (p = 0.967).
3.3. Acylated Ghrelin Levels
At baseline, the levels of acylated ghrelin were 77.8 (196.2) pg/mL in the CPH group, and 24.9
(20.8) pg/mL in the placebo group. Adjusted for time and visit, the acylated ghrelin levels were on
average 51.1 pg/mL higher for the CPH group compared to placebo, but the linear mixed effects model
with repeated measures analysis did not reveal any statistically significant differences between the
groups (95% CI: (−54.5, 157.0), p = 0.330). We observed no statistically significant change in acylated
ghrelin levels from baseline to end of study visit in either of the groups (overall change: 0.03 pg/mL,
95% CI: (−1.50, 1.53), p = 0.937) (Figure 3). There were no significant interactions between group and
visit (baseline vs. end of study, p = 0.749), group and time (p = 0.693), time and visit (p = 0.794) or
between group, visit and time (p = 0.853) for acylated ghrelin.
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IL-8, pg/mL  0.174 
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Hs-CRP; high-sensitivity C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor alpha. The 
data are presented ad median and interquartile range. (1) p-values within groups are based on 
Wilcoxon`s Signed Rank Test. (2) p-values between groups are based on Mann Whitney U Test. 
Statistically significant p-values are marked with an asterisk (*). 
No differences between the groups were observed for hs-CRP or any of the other inflammatory 
mediators at baseline. The concentrations of IL-1β, IL-6, IL-8 or TNF-α did not change during the 
Figure 3. Fasting and postprandial acylated levels of ghrelin after a standardized breakfast meal at
baseline (solid line) and end of study (dotted line) in participants that received supplementation with
cod protein hydrolysate (CPH) (n = 15) (a) or placebo (n = 15) (b) for 8 weeks. In the CPH group, one
individual had much higher levels of acylated ghrelin compared to the rest of the group and is shown
as a separate segment on the graph. Graph (c) presents the change (calculated as 8 weeks—baseline) in
acylated ghrelin during the intervention in the CPH group (solid line) compared to the placebo group
(dotted line).
No correlations were observ d betw en fasting concentration of acylated ghr lin and body weight
(kg) (r = 0.075, p = 0.700) or BMI ( = 0.172, p = 0.372) for the w ole group at baseline (results are
presented for n = 29, one participant exclude from the correlation analysi due to high levels).
Furthermore, no cor elations were observed betwe n changes in fasting acylated ghrelin levels and
changes in body weight (kg) (r = − . 4, p 0.146, p = 0. 48).
3.4. Inflammatory Parameters
The values of hs-CRP and inflammatory markers in serum are shown in Table 2. The serum
concentrations of the cytokines were low, but detectable.
No differences between the groups were observed for hs-CRP or any of the other inflammatory
mediators at bas line. The concentrations of IL-1β, IL-6, IL-8 or TNF-α did not change duri g the
course of the study and were not affected by supplementation with CPH (Table 2). After 8 weeks,
the fasting level of hs-CRP was significantly higher within the CPH group, with no changes observed
within the placebo group (Table 2). The median hs-CRP change in the CPH group was 0.1 (0.0, 2.0) mg/L,
and −0.1 (−1.0, 0.55) mg/L in the placebo group. When comparing the change in f sting levels of
hs-CRP, the distribution in the CPH group was significantly different from the placebo group (p = 0.029)
(Table 2). Two participants in the placebo group were excluded from the statistical analysis of hs-CRP
due to the use of lipid-lowering drugs (simvastatin, atorvastatin), because these are known to affect the
levels of hs-CRP [37]. The statistical significance of results did not change if they were included in the
statistical analysis of hs-CRP.
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Table 2. The concentration of inflammatory markers in serum samples collected before and after 8
weeks supplementation with cod protein hydrolysate (CPH) (n = 15) or placebo (n = 15).
Baseline 8 Weeks
p-Value 1 p-Value 2
Median 25th, 75thPercentile Median
25th, 75th
Percentile
Hs-CRP, mg/L 0.029 *
CPH 4.0 1.0, 4.0 4.0 2.0, 6.0 0.021 *
Placebo 3.0 1.5, 7.0 3.0 2.0, 7.0 0.389
IL-1β, pg/mL 0.567
CPH 0.13 0.13, 0.41 0.13 0.13, 0.41 0.574
Placebo 0.13 0.13, 0.41 0.13 0.13, 0.41 0.589
IL-6, pg/mL 0.935
CPH 1.04 0.52, 1.77 0.90 0.74, 1.48 0.394
Placebo 1.19 0.75, 1.34 1.04 0.59, 1.34 0.396
IL-8, pg/mL 0.174
CPH 15.8 11.9, 20.3 17.6 14.0, 22.5 0.096
Placebo 18.1 15.1, 26.9 16.7 12.2, 23.0 0.281
TNF-α, pg/mL 0.935
CPH 0.57 0.22, 0.93 0.93 0.22, 0.93 0.573
Placebo 0.22 0.11, 0.93 0.57 0.22, 0.93 0.280
Hs-CRP; high-sensitivity C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor alpha. The data are
presented ad median and interquartile range. (1) p-values within groups are based on Wilcoxon’s Signed Rank Test.
(2) p-values between groups are based on Mann Whitney U Test. Statistically significant p-values are marked with
an asterisk (*).
3.5. Adverse Effects
The blood tests taken for safety purposes were all within normal range. Seven subjects reported
discomfort during the intervention period: four in the CPH group and three in the placebo group.
In the CPH group, two subjects reported heartburn, two reported nausea at the beginning of the
intervention period, and one reported that the supplement tasted bad and caused retching. In the
placebo group, one reported itchy rash in the face, one reported nausea and one reported myalgia, but
all three subjects were unsure if the symptoms were related to the intervention.
4. Discussion
The main objective of the present study was to investigate whether daily supplementation with
low doses of CPH for 8 weeks would have an effect on circulating levels of ghrelin, adiponectin,
leptin and different inflammatory markers in subjects with MetS. We hypothesized that 8 weeks
supplementation with CPH would lead to a beneficial effect on circulating leptin levels and reduced
inflammatory markers, as well as increased circulating levels of adiponectin and a suppressing effect
on postprandial levels of ghrelin. These possibly beneficial effects were hypothesized to occur due to
the presences of small peptides, mainly di- and tripeptides, suggested to be absorbed rapidly from
the gastrointestinal tract and possibly influencing pathways involved in regulation of appetite and
inflammation. Here, we show that 4 g of CPH for 8 weeks did not influence fasting and postprandial
concentrations of acylated ghrelin or fasting levels of adiponectin, leptin or the inflammatory markers,
when compared to placebo in individuals with MetS.
A daily supplementation with 4 g of CPH was sufficient to increase fasting serum adiponectin
levels within the CPH group, with no change in serum levels of leptin in circulation. These results are
in agreement with a previous study in healthy overweight and obese subjects receiving 2.5 g of cod
protein (not hydrolyzed) for 8 weeks [23]. Observing the individual levels of adiponectin (Figure 2a),
it is apparent that there are individual variations. Since the increased levels of adiponectin only were
found within the CPH group and not when comparing the groups after intervention, the results should
be interpreted with caution and should be explored in further studies. Still, these findings are of
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interest and suggests that hydrolyzed protein from lean fish may have beneficial effects on adiponectin
concentration. We hypothesize that an effect may be mediated by rapidly absorbed di- and tripeptides
present in the hydrolyzed supplement, containing bioactive sequences affecting metabolic pathways in
the cells and thereby increasing the levels of adiponectin. Compared to the recommended daily protein
intake in healthy individuals (e.g., 0.8–1.5 g protein/kg body weight/day) [38], the amount of protein in
the supplement is very low, and it is plausible that it is not the increased protein content per se that
is responsible for the possible metabolic effect. Bioactive peptide sequences with effect on glucose
metabolism, blood pressure and lipids have been identified in other fish protein hydrolysates [39].
We have not tested for the presences of these specific known bioactive sequences in our hydrolysate,
which is a limitation of the study, and the possible mechanism of action is therefore only a hypothesis.
No effects on fasting or postprandial levels of acylated ghrelin were observed after supplementation
with CPH, which is in line with what we observed after giving one single dose of CPH to normal
weight adults [29]. In contrast to our previous study, we used a higher dose, over a longer period,
and a population with metabolic disturbances in the current study. We still did not observe any effects
on circulating acylated ghrelin. In the previous study we assessed self-reported feeling of satiety and
hunger [29]. An assessment of appetite was not included, which would have been an improvement
of the study design seen in relation to ghrelin. By including validated questionnaires for reporting
appetite and a free eating lunch at each study visit, we would be able to calculate energy intake
and assess whether supplementation with CPH for 8 weeks led to lower energy intake, and thereby
suggesting a suppressing effect on appetite.
Fish has been proposed to have anti-inflammatory properties, and reduced levels of CRP have been
linked to fish consumption [13]. A diet with cod protein reduced the levels of hs-CRP in insulin-resistant
subjects [14], whereas others have reported of no effect on CRP levels or other inflammatory markers
after a high intake of cod in normal-weight [40] or overweight subjects [41]. No effect on CRP levels
was observed in an intervention study with overweight and obese subjects supplemented with similar
amount of cod protein (intact protein) as used in the current trial [15]. We observed higher levels of
hs-CRP after supplementation with CPH for 8 weeks, when compared to placebo, but did not observe
any changes in other inflammatory markers. An increased level of CRP was reported in elderly subjects
living in a nursing home setting given 5.2 g of fish protein (blue whiting) for 6 weeks (compared to
placebo) [42], however, this group is not comparable to our study population. Overall, the higher
levels of hs-CRP in the CPH group is difficult to interpret. It is possible that the small sample size
might have influenced the results, or that some individuals may have had some on-going low-grade
inflammation without disclosing a problem. When comparing the overall fasting levels of hs-CRP in
both groups in our study with a previous study by Delongui et al. [43], our levels are similar to the
levels reported in obese subjects and higher compared to normal weight subjects, emphasizing how
BMI may affect CRP levels [43].
There are certain strengths and limitations to the study. Firstly, the randomized, double-blinded
design is a strength. A cross-over design would potentially have been an even better design, with each
subject serving as his/her own control and allowing us to recruit fewer subjects without compromising
the strength of the study [44]. Since this would have resulted in a long intervention period and
possibly higher dropout rate, we chose to conduct the current study as a parallel group study. Secondly,
adjusting the CPH dosage to the body weight of each participant could have further strengthened
the design, as it would reduce the effect of variation in body weight. It was not practically feasible,
and we chose to use a dose similar to what has previously been effective [15,36,45]. Thirdly, the lack of
a power analysis is a weakness when interpreting the data, but there was no relevant data to base such
calculation upon. As we had difficulties recruiting, we did not reach our target of 60 subjects (with 30
individuals in each treatment arm), which might have further affected the results. In particular we had
difficulties recruiting males and a predominance of female participants were included in the study. Due
to limited resources and time constraint, the inclusion of new participants was stopped in September
2019. It cannot be ruled out that our results might have changed in a larger study, so replication from
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future studies are necessary to examine the robustness of our findings, in particular related to fasting
levels of serum adiponectin and hs-CRP.
5. Conclusions
To conclude, our study showed that a daily supplement of 4 g of CPH for 8 weeks was not
sufficient to affect fasting or postprandial levels of ghrelin, or fasting levels of adiponectin, leptin or
inflammatory markers in overweight and obese subjects with MetS.
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